{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:54:15Z","timestamp":1780566855545,"version":"3.54.1"},"reference-count":30,"publisher":"BMJ","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart"],"accepted":{"date-parts":[[2000,9,12]]},"published-print":{"date-parts":[[2001,2,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To determine the outcome of heart transplantation for end stage amyloid heart disease in patients treated at a single centre.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>DESIGN<\/jats:title>\n                  <jats:p>Records of all patients with amyloid heart disease who underwent heart transplantation were examined to determine survival, graft involvement by amyloid, the course of systemic amyloid disease, and the cause of death.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PATIENTS<\/jats:title>\n                  <jats:p>10 patients, mean (SD) age 54 (8) years, received transplants in the 13 year period 1984 to 1997.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Two patients, both with AL amyloid (primary systemic amyloidosis), died perioperatively. Mean follow up in the remaining eight patients was 49.9 (39.5) months (range 3\u2013116 months). Amyloid deposits in the grafts became evident histologically in five patients with AL amyloid at 5, 11, 12, 28, and 30 months after transplantation, and in one patient with familial amyloid at 60 months. Echocardiography showed no evidence of left ventricular systolic impairment at the time of recurrence. Seven patients died, at 3, 11, 26, 32, 49, 85, and 116 months after transplantation; four of these deaths were related to amyloidosis. Actuarial survival at one and two years was 60% and at five years, 30%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Heart transplantation for amyloid heart disease remains controversial because of the scarcity of hearts for transplantation, the systemic nature of amyloidosis, and the potential for amyloid deposition in the graft. Postoperative mortality was high (20%), reflecting extracardiac amyloid. Heart transplantation for end stage cardiac amyloidosis is feasible but, without treatment of the underlying process, it is a palliative procedure.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heart.85.2.202","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T06:37:59Z","timestamp":1027751879000},"page":"202-207","source":"Crossref","is-referenced-by-count":83,"title":["Long term results of heart transplantation in patients with amyloid heart disease"],"prefix":"10.1136","volume":"85","author":[{"given":"S W","family":"Dubrey","sequence":"first","affiliation":[{"name":"aTransplant Unit, Harefield Hospital, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex UB9 6JH, UK, \n\nbDepartment of Pathology, Harefield Hospital, \n\ncNational Amyloidosis Centre, Royal Free Hospital, London NW3 2PF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M M","family":"Burke","sequence":"additional","affiliation":[{"name":"aTransplant Unit, Harefield Hospital, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex UB9 6JH, UK, \n\nbDepartment of Pathology, Harefield Hospital, \n\ncNational Amyloidosis Centre, Royal Free Hospital, London NW3 2PF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Khaghani","sequence":"additional","affiliation":[{"name":"aTransplant Unit, Harefield Hospital, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex UB9 6JH, UK, \n\nbDepartment of Pathology, Harefield Hospital, \n\ncNational Amyloidosis Centre, Royal Free Hospital, London NW3 2PF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P N","family":"Hawkins","sequence":"additional","affiliation":[{"name":"aTransplant Unit, Harefield Hospital, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex UB9 6JH, UK, \n\nbDepartment of Pathology, Harefield Hospital, \n\ncNational Amyloidosis Centre, Royal Free Hospital, London NW3 2PF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M H","family":"Yacoub","sequence":"additional","affiliation":[{"name":"aTransplant Unit, Harefield Hospital, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex UB9 6JH, UK, \n\nbDepartment of Pathology, Harefield Hospital, \n\ncNational Amyloidosis Centre, Royal Free Hospital, London NW3 2PF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N R","family":"Banner","sequence":"additional","affiliation":[{"name":"aTransplant Unit, Harefield Hospital, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex UB9 6JH, UK, \n\nbDepartment of Pathology, Harefield Hospital, \n\ncNational Amyloidosis Centre, Royal Free Hospital, London NW3 2PF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2001,2,1]]},"reference":[{"key":"2025101723535091000_85.2.202.1","doi-asserted-by":"publisher","DOI":"10.1126\/science.172.3988.1150"},{"key":"2025101723535091000_85.2.202.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709253371306"},{"key":"2025101723535091000_85.2.202.3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood.V77.2.257.257","article-title":"Response rates and survival in primary systemic amyloidosis.","volume":"77","author":"Gertz","year":"1991","journal-title":"Blood"},{"key":"2025101723535091000_85.2.202.4","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/91.2.141"},{"key":"2025101723535091000_85.2.202.5","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.28.2.73"},{"key":"2025101723535091000_85.2.202.6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.16.7389"},{"key":"2025101723535091000_85.2.202.7","doi-asserted-by":"publisher","DOI":"10.1038\/362553a0"},{"key":"2025101723535091000_85.2.202.8","doi-asserted-by":"publisher","DOI":"10.1038\/ng0393-252"},{"key":"2025101723535091000_85.2.202.9","first-page":"346","article-title":"Successful intermediate-term outcome for patients with cardiac amyloidosis undergoing heart transplantation: results of a multicenter survey.","volume":"9","author":"Hosenpud","year":"1990","journal-title":"J Heart Transplantation"},{"key":"2025101723535091000_85.2.202.10","first-page":"338","article-title":"Progression of systemic disease and reduced long term survival in patients with cardiac amyloidosis undergoing heart transplantation.","volume":"84","author":"Hosenpud","year":"1991","journal-title":"Circulation"},{"key":"2025101723535091000_85.2.202.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199008233230803"},{"key":"2025101723535091000_85.2.202.12","doi-asserted-by":"publisher","DOI":"10.1007\/BF01254559"},{"key":"2025101723535091000_85.2.202.13","unstructured":"Criteria Committee, New York Heart Association, Inc (1964) Diseases of the heart and blood vessels. Nomenclature and criteria for diagnosis (Little, Brown and Co, Boston), 6th ed. p 114."},{"key":"2025101723535091000_85.2.202.14","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases.","volume":"32","author":"Kyle","year":"1995","journal-title":"Semin Hematol"},{"key":"2025101723535091000_85.2.202.15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/01.CIR.73.2.249","article-title":"Echocardiographic assessment of the evolution of amyloid heart disease: a study with familial amyloid polyneuropathy.","volume":"73","author":"Hongo","year":"1986","journal-title":"Circulation"},{"key":"2025101723535091000_85.2.202.16","first-page":"587","article-title":"A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group.","volume":"9","author":"Billingham","year":"1990","journal-title":"J Heart Transplant"},{"key":"2025101723535091000_85.2.202.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.309.6962.1135"},{"key":"2025101723535091000_85.2.202.18","first-page":"655","article-title":"The registry of the International Society for Heart and Lung Transplantation: thirteenth official report\u20141996.","volume":"15","author":"Hosenpud","year":"1996","journal-title":"J Heart Lung Transplant"},{"key":"2025101723535091000_85.2.202.19","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.92.12.3593"},{"key":"2025101723535091000_85.2.202.20","first-page":"165","article-title":"Heart transplantation for cardiac amyloidosis: successful one year outcome despite recurrence of the disease.","volume":"7","author":"Conner","year":"1988","journal-title":"J Heart Transplant"},{"key":"2025101723535091000_85.2.202.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)80214-8"},{"key":"2025101723535091000_85.2.202.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00806-0"},{"key":"2025101723535091000_85.2.202.23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1042\/cs0870289","article-title":"Studies with radiolabelled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo.","volume":"87","author":"Hawkins","year":"1994","journal-title":"Clin Sci"},{"key":"2025101723535091000_85.2.202.24","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)93127-M"},{"key":"2025101723535091000_85.2.202.25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0272-6386(95)90647-9","article-title":"Treatment of amyloidosis.","volume":"26","author":"Tan","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"2025101723535091000_85.2.202.26","unstructured":"Pepys MB. Pathogenesis, diagnosis and treatment of systemic amyloidosis. In: Dobson CM, Ellis RJ, Fersht AR, eds.Protein misfolding and disease. London: The Royal Society (Philosophical Transactions of the Royal Society of London (B)), (in press)."},{"key":"2025101723535091000_85.2.202.27","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1182\/blood.V88.7.2801.bloodjournal8872801","article-title":"Dose-intensive melphalan with blood stem-cell support for the treatment of AL amyloidosis: one year follow up in five patients.","volume":"88","author":"Comenzo","year":"1996","journal-title":"Blood"},{"key":"2025101723535091000_85.2.202.28","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00772.x"},{"key":"2025101723535091000_85.2.202.29","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V91.10.3662","article-title":"Dose-intensive melphalan with blood stem-cell support for the treatment of AL amyloidosis: survival and responses in 25 patients.","volume":"91","author":"Comenzo","year":"1998","journal-title":"Blood"},{"key":"2025101723535091000_85.2.202.30","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199807270-00016"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heart.85.2.202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T06:53:59Z","timestamp":1760770439000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heart.85.2.202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2,1]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2001,2,1]]},"published-print":{"date-parts":[[2001,2,1]]}},"alternative-id":["10.1136\/heart.85.2.202"],"URL":"https:\/\/doi.org\/10.1136\/heart.85.2.202","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,2,1]]}}}